R. Michael Smullen is Co-Founder, CEO, and Chairman, for AltMed Enterprises. AME is a nationally recognized medical cannabis company with operations in Arizona and Florida.
Michael spent 31 years in the pharmaceutical and biotech industries building and leading commercial operations for several companies including three start-ups.
Before founding AltMed Enterprises in 2014, Michael, a Senior Executive at MedImmune, was responsible for building a world class commercial organization and successfully launching the first monoclonal antibody approved in the US for an infectious disease. The drug, Synagis, became the 9th most successful biotech product of all time.
While at MedImmune, Michael also headed up the company’s managed care, government affairs, sales operations, trade and distribution, and sales training departments. During this time, revenues grew from $35 Million in 1996, to more than $1 Billion in the US in 2005.
In 2007, Michael was part of an executive team that secured a company buy out from Astra Zeneca for $15.8 Billion.
Michael was inspired to enter into the medical cannabis industry and launch AltMed Enterprises following years of watching his youngest daughter, who is epileptic, struggle with the debilitating side effects of the pharmaceutical drugs she was on to help control her seizures.
AltMed Enterprises, while it continues to build out its 30 dispensaries throughout Florida, expects to have their medical cannabis line of products, branded as MÜV™, licensed in several states outside of Florida and Arizona in 2019.
Michael is a graduate of Norwich University and holds degrees in History and Criminal Justice.